R&G PharmaStudies (301333) Stock Overview
Operates as a clinical trial outsourcing service provider in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
301333 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
R&G PharmaStudies Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥69.48 |
| 52 Week High | CN¥91.78 |
| 52 Week Low | CN¥42.78 |
| Beta | 0.70 |
| 1 Month Change | 13.53% |
| 3 Month Change | -3.61% |
| 1 Year Change | 47.67% |
| 3 Year Change | -0.73% |
| 5 Year Change | n/a |
| Change since IPO | 23.51% |
Recent News & Updates
Recent updates
R&G PharmaStudies Co., Ltd. Just Missed Revenue By 5.8%: Here's What Analysts Think Will Happen Next
Mar 31
We Think R&G PharmaStudies (SZSE:301333) Can Stay On Top Of Its Debt
Feb 11R&G PharmaStudies' (SZSE:301333) Conservative Accounting Might Explain Soft Earnings
Nov 06R&G PharmaStudies' (SZSE:301333) Dividend Will Be Reduced To CN¥0.20
Jul 01Is There An Opportunity With R&G PharmaStudies Co., Ltd.'s (SZSE:301333) 27% Undervaluation?
Jun 06Shareholders Will Be Pleased With The Quality of R&G PharmaStudies' (SZSE:301333) Earnings
Apr 29Shareholder Returns
| 301333 | CN Life Sciences | CN Market | |
|---|---|---|---|
| 7D | 3.1% | 3.2% | 1.5% |
| 1Y | 47.7% | 65.8% | 33.4% |
Return vs Industry: 301333 underperformed the CN Life Sciences industry which returned 65.8% over the past year.
Return vs Market: 301333 exceeded the CN Market which returned 33.4% over the past year.
Price Volatility
| 301333 volatility | |
|---|---|
| 301333 Average Weekly Movement | 7.1% |
| Life Sciences Industry Average Movement | 6.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in CN Market | 9.9% |
| 10% least volatile stocks in CN Market | 4.1% |
Stable Share Price: 301333 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 301333's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 2,208 | David Wu | www.rg-pharma.com |
R&G PharmaStudies Co., Ltd. operates as a clinical trial outsourcing service provider in China and internationally. It provides drug clinical research and development integrated services. The company’s services include clinical trial operation, clinical trial site management, biological sample testing, data management and statistical analysis, clinical trial consulting, and clinical pharmacology services.
R&G PharmaStudies Co., Ltd. Fundamentals Summary
| 301333 fundamental statistics | |
|---|---|
| Market cap | CN¥6.67b |
| Earnings (TTM) | CN¥136.90m |
| Revenue (TTM) | CN¥851.01m |
Is 301333 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 301333 income statement (TTM) | |
|---|---|
| Revenue | CN¥851.01m |
| Cost of Revenue | CN¥555.36m |
| Gross Profit | CN¥295.64m |
| Other Expenses | CN¥158.74m |
| Earnings | CN¥136.90m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Apr 28, 2026
| Earnings per share (EPS) | 1.43 |
| Gross Margin | 34.74% |
| Net Profit Margin | 16.09% |
| Debt/Equity Ratio | 0% |
How did 301333 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/16 16:47 |
| End of Day Share Price | 2026/04/16 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
R&G PharmaStudies Co., Ltd. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jin Zhang | China International Capital Corporation Limited |
| Shitong Han | Citic Securities Co., Ltd. |
| Yuan Yuan Sun | Industrial Securities Co. Ltd. |